Automated, intelligent oral contraception prescribing via telemedicine - using AI to improve patient health outcomes and streamline time-intensive assessment processes, exacerbated by COVID-19

Covid 19通过紧急引入自动化和在可行的情况下利用远程医疗来减少资源压力，特别是在第二波/未来高峰的情况下，验证并加剧了(在国民健康保险长期计划中确定的)提高效率的必要性。新冠肺炎的持续影响意味着超过45%的非紧急预约被取消或推迟，留下大量积压的全科医生。避孕和口服避孕药处方(OC)是英国人去全科医生就诊的第二大常见原因，每年有超过2000万次的预约，相当于13,900天，被归类为非紧急。54%的性健康诊所通常由年轻女性用于避孕咨询，导致许多人没有支持，这进一步加剧了这一情况。NHS长期/NIHR后Covid战略中确定的智能、自动化技术可以在这方面提供帮助，特别是当与最近管理的关于荷尔蒙状况的大型女性健康数据相结合时。减少对全科医生诊所的需求，同时通过确保第一次开出最佳可用的药物来改善处方流程(52%的用户在第一次开出的药物上出现副作用，平均导致两次进一步的会诊以管理不良副作用和确定最佳药物)。基于我们的CE标记的激素健康平台和原型TRL5患者分层算法，我们打算开发和试验(与NHS合作伙伴CNWL NHS Trust)一个新的远程医疗平台，用于女性避孕治疗，将；*自动化咨询和分诊过程*通过患者分层(利用先进的算法)智能/准确地选择最佳可用的OC，该分层考虑女性独特的激素谱*由我们的数字支持中心进行持续的远程推广和监测--\&gt；更早地检测副作用，在必要时通过咨询/指导/用药改变来缓解。**影响**该项目既解决了当前处方方法中长期低效的问题，也解决了新冠肺炎对全科医生/初级保健的直接影响。这项技术将明确：1.通过远程分诊，70%的病例不需要全科医生：节省约9730个全科医生-天/天。通过我们针对GP的CE标记知识库，改进剩余30%复杂病例的分诊流程。通过人工智能辅助患者分层，提高用药处方的准确性，减少约60%的复诊。通过我们的合作伙伴Pharmacy2U和Mayberry\_Pharmacy5启用远程处方。帮助减少NHS因激素药物相关副作用而产生的约19亿GB的费用(NHS：2019)6.通过数字推广和互动改善患者护理和主动管理。可以迅速在全国范围内大规模推广。

Covid 19 has validated and compounded the need for improved efficiencies (identified within the NHS Long Term plan) via the urgent introduction of automation and the utilisation of Telemedicine where feasible to reduce strain on resources, especially with the prospect of a second wave/future spikes on the horizon.The ongoing impact of Covid-19 meant over 45% of non-urgent appointments were either cancelled or postponed, leaving GP's with significant backlogs. Contraception and prescription of Oral Contraceptives (OC) is the second most common reason to visit a GP (UK), accounting for more than 20m appointments/annum, equivalent to 13,900 days and is classed as "non-urgent."This has been further compounded by the closure of 54% of Sexual Health Clinics, often utilised by young females for contraceptive consultations, leaving many unsupported.Intelligent, automated technology, as identified in the NHS Long-Term/NIHR post-Covid strategies, can help in this regard in particular when combined with recently curated large female health datasets on hormonal profiles. Reducing demand on GP clinics whilst improving the prescribing process by ensuring optimum available medication is prescribed first time (52% of users suffer side-effects on the first prescribed medication, on average resulting in 2 further consultations to manage adverse side-effects and determine optimum medication).Building upon our CE-Marked hormonal health platform and prototype TRL5 patient stratification algorithms, we intend to develop and trail (alongside NHS partner CNWL NHS Trust) a new Telemedicine platform for female contraceptive treatments that will;* Automate the consultation and triage process* Intelligently/accurately select the optimum available OC via patient stratification (utilising advanced algorithms) that considers a woman's unique hormone profile* Ongoing remote outreach and monitoring by our digital support hub-\> earlier detection of side-effects, mitigation through counselling/coaching /medication changes where warranted.**Impact**The project addresses both a long-term inefficiency in the current prescribing method, as well as addresses the immediate impact of COVID-19 on GPs/Primary Care. The technology will explicitly;1. Remove the need for a GP in 70% of all cases via remote triage: saving ~9730 GP-days/annum.2. Improve the triage process for remaining 30% of complex cases via our CE-Marked knowledge base for GPs.3. Improve the accuracy of medication prescription through AI-assisted patient stratification, reducing re-consultations by ~60%.4. Enable remote prescribing via our partners Pharmacy2U&Mayberry\_Pharmacy5. Help reduce the ~£1.9Bn cost to the NHS of hormonal medication related side-effects(NHS:2019)6. Improve patient care and proactive management through digital outreach and interaction.7. Can be rolled out nationally, at scale, quickly.